A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi et al.
Research Article — Peer-Reviewed Source
Original research published by Newsome et al. in New England Journal of Medicine. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
This phase 2 trial involving patients with NASH showed that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution than placebo. However, the trial did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT02970942.).
Full text is available at the publisher.
Read at Publisher| DOI | 10.1056/nejmoa2028395 |
| Journal | New England Journal of Medicine |
| Year | 2020 |
| Authors | Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J. Sanyal, Anne‐Sophie Sejling, Stephen A. Harrison |
| License | Open Access — see publisher for license terms |
| Citations | 1,814 |